代謝治療薬の世界市場：2023-2030

市場概要

代謝治療薬の世界市場は、2022年に160億9,436万米ドル、2030年には263億6,952万米ドルと予測され、予測期間を通じてCAGRは6.5%となる見込みです。

フェニルケトン尿症は、アミノ酸であるフェニルアラニンを体内で分解できない病気であり、遺伝的な代謝異常の一例です。また、1型糖尿病、ゴーシェ病、メープルシロップ尿症、シスチン症、ファブリー病、ハートナップ病、ハンター症候群、ハーラー症候群、フォン・ギアケ病、遺伝性ヘモクロマトーシスなどの代謝性疾患が知られています。

代謝異常の治療は、病気の根本的な原因を治療し、代謝機能を最適に保つための薬剤を使用することで、代謝のバランスを回復させることです。

市場力学

代謝異常の有病率の増加

フェニルケトン尿症、シトルリン血症、メープルシロップ尿症などの代謝性疾患の有病率の増加や治療費の高さが、これらの疾患の治療薬市場の成長に寄与しています。また、発展途上国における可処分所得の増加や、ヘルスケアインフラの整備が進んでいることも、成長の要因となっています。

アミノ酸サプリメントの費用負担の増加

動物の発育、生殖などの機能をサポートし、動物のタンパク質需要を満たすために、動物用飼料の生産者の間でアミノ酸の需要が増加すると予測されています。アミノ酸が不足すると、動物の発育が遅れたり、成熟が遅れたり、免疫や代謝の刺激に対する反応が鈍くなったり、低体重になったり、さまざまな健康上の問題を引き起こす可能性があります。

そのため、アミノ酸は動物用飼料の調製において、より重要なものとなってきています。動物飼料分野におけるアミノ酸のニーズは、肉の消費量と需要の増加、家畜の生産量の増加にも後押しされています。

代謝治療薬に関連する副作用

代謝治療薬に関連する悪影響がある特徴として、心拍数や血圧の上昇、胃腸障害、不眠症や睡眠障害、口の渇きなどが挙げられます。

例えば、日本に本社を置く製薬会社のアステラス製薬は、2022年6月、USFDAが、成人の遅発性ポンペ病に対するAAV遺伝子置換療法の治験であるAT845試験を評価しながら、現在フェーズ1/2試験中のFORTISに臨床保留をかけたと発表しました。

COVID-19影響分析

代謝性疾患を治療する医薬品の需給は、COVID-19のパンデミックによって影響を受けています。COVID-19ワクチンが研究機関や製薬企業の1次調査になったため、質量分析装置やクロマトグラフィーなどの代謝関連研究ツールの売上はやや減少しています。このため、代謝に影響を与える医薬品の市場は、2020年に大きく落ち込むと予想されます。

ロシア・ウクライナ紛争分析

ロシアのウクライナ侵攻は、世界中の何百万人もの人々に影響を及ぼしています。医薬品開発企業は、開発プロセスの遅延、事業継続性の喪失、既に発売されている医薬品のコンプライアンス違反の危険性に直面することになります。

ロシア・ウクライナ紛争は、研究開発への投資に影響を与え、原材料の輸出入が停止し、投資家の関心も低くなり、新陳代謝の激しい医薬品市場に影響を及ぼしています。

目次

第1章 調査手法とスコープ

• 調査手法
• 調査目的および調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

• 薬効分類別スニペット
• 適応症別スニペット
• 販売チャネル別スニペット
• 地域別スニペット

第4章 市場力学

• 影響要因
  • 促進要因
    • アミノ酸代謝の普及
  • 抑制要因
    • 代謝促進剤に伴う副作用
  • 機会
    • アミノ酸サプリメントと健康効果に関する費用の増加
  • 影響分析

第5章 産業分析

• ポーターの5フォース分析
• サプライチェーン分析
• 価格設定分析
• 法規制の分析

第6章 COVID-19の分析

• COVID-19の分析
  • COVID-19の前のシナリオ
  • COVID-19実施中のシナリオ
  • COVID-19後のシナリオ
• COVID-19の中での価格・ダイナミクス
• 需給スペクトル
• パンデミック時の市場に関連する政府の取り組み
• メーカーの戦略的な取り組み
• サマリー

第7章 薬効分類別

• 抗糖尿病薬
• 脂質低下剤
• 抗肥満薬
• 甲状腺ホルモン剤
• その他

第8章 適応症別

• 糖尿病
• 高脂血症
• 肥満症
• 甲状腺機能低下症

第9章 流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋地域
• 中東・アフリカ地域

第11章 競合情勢

• 競合シナリオ
• 市況ポジショニング/シェア分析
• M&A（合併・買収）分析

第12章 企業プロファイル

• Merck Sharp and Dohme Corp
• Novartis AG
• Amicus Therapeutics
• AstraZeneca
• Boehringer Ingelheim International GmbH
• Takeda Pharmaceutical Company Limited
• Sanofi
• GlaxoSmithKline Plc
• Horizon Therapeutics
• BioMarin Pharmaceuticals

第13章 付録

Market Overview

The Global Metabolism Drugs Market is expected to be valued at USD 16,094.36 million in 2022 and USD 26,369.52 million by 2030, with a CAGR of 6.5% throughout the forecast period.

Phenylketonuria, a disease in which the body is unable to break down the amino acid phenylalanine, is an illustration of a genetic metabolic disorder. Several more well-known metabolic diseases include type 1 diabetes, Gaucher's disease, maple syrup urine disease, cystinosis, Fabry disease, Hartnup disease, Hunter syndrome, Hurler syndrome, Von Gierke disease, and hereditary hemochromatosis.

By treating the underlying cause of the illness and employing medications to preserve optimal metabolic function, the treatment for metabolic disorders entails restoring metabolic balance.

Market Dynamics

Increasing Prevalence Of Metabolic Disorders

The increasing prevalence of metabolic disorders like phenylketonuria, citrullinemia, and maple syrup urine disease, as well as the high cost of treatments, have all contributed to the growth of the market for treatments for these disorders. Other factors driving this growth include rising disposable income in developing nations and the advancement of healthcare infrastructure.

The Rising Expense of Amino Acid Supplements

The demand for amino acids is predicted to increase among producers of animal feed in order to support animal development, reproduction, and other functions as well as to meet the animals' need for protein. Any amino acid deficit may cause animals to develop slowly, mature later, respond less quickly to immunological or metabolic stimuli, have low body weights, and have various health issues.

As a result, amino acids are becoming more crucial in the preparation of animal feed. The need for amino acids in the animal feed sector is also being driven by rising meat consumption and demand, as well as rising livestock output.

Side Effects Associated With Metabolism Drugs

Among the characteristics that have negative effects associated with drugs for metabolic disorders are increased heart rate and blood pressure, gastrointestinal issues, insomnia and sleep disturbance, dry mouth, etc.

For instance, Astellas Pharma, a pharmaceutical company based in Japan, in June 2022, announced that the USFDA put a clinical hold on FORTIS, which is currently undergoing a Phase 1/2 trial while evaluating the AT845 trial, which was an investigational AAV gene replacement therapy for adults with Late Onset Pompe Disease.

COVID-19 Impact Analysis

The supply and demand for medications that treat metabolic disorders have been affected by the COVID-19 pandemic. Since the COVID-19 vaccine is now the primary focus of research institutions and pharmaceutical corporations, sales of mass spectrometry, chromatography, and other metabolism-related research tools have somewhat decreased. The market for medications that affect metabolism is thus anticipated to see a significant drop in 2020.

Russia- Ukraine Conflcit Analysis

Russia's invasion of Ukraine affects millions of people worldwide. Drug developers are bound to face delays throughout the development process, a loss of business continuity, and the danger of non-compliance for pharmaceuticals already on the market.

The Russia-Ukraine conflict affected the investments in R&D due to which the import and exports of raw materials stopped and also investors were showing less interest during that period, which was affecting the metabolism drugs market.

Segment Analysis

The Diabetes Segment Will Dominate The Market In The Forecast Period.

The diabetes segment is estimated to hold about 35.6% of the global metabolism drugs market as plasma-free fatty acids (FFA) are more prevalent in diabetic individuals, diabetes may affect the way some medicines attach to plasma proteins, perhaps through glycosylation or protein displacement. However, albumin and 1-acid glycoprotein plasma concentrations wouldn't alter. Contrary to experimental research, the majority of medicines' metabolic clearance in people seems to be unaltered or slightly reduced in diabetes.

Geographical Analysis

North America is the Dominating Region During The Forecast Period.

Geographically, there are four regions that make up the worldwide market for metabolic disorders: North America, Europe, Asia Pacific, and the rest of the world (RoW). Due to the availability of cutting-edge technology and the greater penetration of diabetes care services throughout the region, North America is anticipated to lead the market throughout the projected period. North America is estimated to hold about 37.8% of the global metabolism drugs market.

Due to the high incidence of diabetes among the elderly population, the United States constituted a significant regional contributor. Over 25% of Americans with diabetes are 65 years of age or older, according to the American Diabetes Association. Over the projected period, Asia Pacific is anticipated to overtake North America as the region with the largest market for metabolic disorders. The region's healthcare reforms and an increase in the number of diabetics, particularly in India, are expected to drive the growth of the Asia Pacific market.

Competitive Landscape

The major global players include: Merck Sharp and Dohme Corp, Novartis AG, Amicus Therapeutics, AstraZeneca, Boehringer Ingelheim International GmbH, Takeda Pharmaceutical Company Limited, Sanofi, GlaxoSmithKline Plc, Horizon Therapeutics, and BioMarin Pharmaceuticals.

• Why Purchase the Report?
• To visualize the global metabolism drugs market segmentation based on the drug class, indication, distribution channels and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global metabolism drugs market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global metabolism drugs market report would provide approximately 92 tables, 108 figures and 195 pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Drug Class
• 3.2. Snippet by Indication
• 3.3. Snippet by Distribution Channels
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increased prevalence of amino acid metabolism
  • 4.1.2. Restraints
    • 4.1.2.1. Side effects associated with metabolism drugs
  • 4.1.3. Opportunity
    • 4.1.3.1. The rising expense of amino acid supplements and Health Benefits
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID-19
  • 6.1.2. Scenario During COVID-19
  • 6.1.3. Scenario Post COVID-19
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Drug Class

• 7.1. Antidiabetic Drugs
• 7.2. Lipid Lowering Drugs
• 7.3. Anti- Obesity Drugs
• 7.4. Thyroid Hormone Drugs
• 7.5. Others

8. By Indications

• 8.1. Diabetes
• 8.2. Hyperlipidemia
• 8.3. Obesity
• 8.4. Hypothyroidism

9. By Distribution Channel

• 9.1. Hospital Pharmacies
• 9.2. Retail Pharmacies
• 9.3. Online Pharmacies

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. The U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. The UK
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Spain
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
  • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. Merck Sharp and Dohme Corp
• 12.2. Novartis AG
• 12.3. Amicus Therapeutics
• 12.4. AstraZeneca
• 12.5. Boehringer Ingelheim International GmbH
• 12.6. Takeda Pharmaceutical Company Limited
• 12.7. Sanofi
• 12.8. GlaxoSmithKline Plc
• 12.9. Horizon Therapeutics
• 12.10. BioMarin Pharmaceuticals

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us